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Background: Ingestion of glucosylceramide improves transepidermal water loss (TEWL) from the skin, but the
underlying mechanism by which a small amount of dietary glucosylceramide can vastly improve skin conditions
remains unclear. In a previous report, glucosylceramides were shown to be digested to sphingoids, which were
shown to be absorbed through the intestinal epithelium. Based on these observations, we hypothesized that
sphingoids are the key molecules facilitating endogenous ceramide production. In this study, we assessed the effect
of 4,8-sphingadienine (d18:2) and 4-hydroxy-8-sphingenine (t18:1), derived from konjac glucosylceramide, on
stimulating ceramide production.
Methods: Konjac glucosylceramide acidolysis was performed using hydrochloric acid; the resulting d18:2 and t18:1
were fractionated by column chromatography. Real-time quantitative RT-PCR was performed to assess the effect of
d18:2 and t18:1 on gene expression in normal human epidermal keratinocytes, while their effect on the nuclear
receptor, peroxisome proliferator-activated receptor (PPAR)γ, was measured using a receptor-cofactor assay system.
The effect of d18:2 and t18:1 on stimulating ceramide production was evaluated using HPTLC analysis in a 3-
dimensional human skin model.
Results: We noted the upregulation of genes related to de novo ceramide synthesis as well as of those encoding
the elongases of very long-chain fatty acids by d18:2 and t18:1, but not by glucosylceramide and 4-sphingenine.
Both these sphingoids also facilitated the expression of PPARβ/δ and PPARγ; moreover, they also demonstrated
ligand activity for PPARγ. These results indicated that d18:2 and t18:1 promote the differentiation of keratinocytes.
Analysis of the lipids within the 3-dimensional human skin model indicated that treatment with d18:2 and t18:1 not
only upregulated gene expression but also increased ceramide production.
Conclusions: The sphingoids d18:2 and t18:1 activated genes related to de novo ceramide synthesis and increased
ceramide production, whereas glucosylceramide and 4-sphingenine could not. These results suggest that the effect
of dietary glucosylceramides on the skin is mediated by d18:2 and t18:1.
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Ceramide is a sphingolipid that is composed of a long-chain
sphingoid base with 2-amide groups linked to a fatty acid
[1,2]. Because of the various combinations of diverse sphin-
goids and fatty acids, ceramide is a generic name used for
more than 10 such molecular species in humans [3]. Cera-
mides are found not only in animals but also in plants and
fungi. Each ceramide has characteristic structures. Ceramides* Correspondence: yigarash@pharm.hokudai.ac.jp
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reproduction in any medium, provided the orderived from plants are mostly glucosylated (glucosylcera-
mide), while the sphingoid residue mainly has a double bond
between C8 and C9 [4]. Fig. 1 shows the typical sphingoid
structures derived from animals and from higher plants.
Sphingoid structures from fungi share features with those
from plants, but, in addition, are methylated at C9 [5,6].
Animal ceramides are present not only in the plasma
membranes of cells but also in the extracellular matrix of
the stratum corneum, where the ceramide content among
the intracellular lipids of the stratum corneum reaches ap-
proximately 50%. Ceramides and their metabolites formal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and

























Figure 1 Structure of animal- and higher plant-type sphingoids. The consensus structure of sphingoids from animals and higher plants. The
higher plant-type is characterized by a double bond between C8 and C9.
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tion in ceramides causes some skin disorders such as
atopic dermatitis [8]. Ceramides are also important in sig-
nal transduction. For example, phosphorylated ceramide
and its metabolites act as an intracellular signaling factor
for inducing apoptosis [9].
Uchiyama et al. reported that dietary glucosylceramides
derived from the konjac tuber reduce transepidermal
water loss (TEWL) from the skin [10]. The mechanism by
which a small amount of dietary glucosylceramides can
improve skin conditions remains unclear. In this study, we
attempted to assess the relationship between dietary gluco-
sylceramides and ceramide production in the skin.
A previous study reported that glucosylceramides are
digested to sphingoids, which are then absorbed though
the intestinal epithelium [11]. Under the hypothesis that
skin condition improvement may be mediated by the sig-
naling function of sphingoids, we assessed the ability of
sphingoids to induce gene expression in normal human
epidermal keratinocytes (NHEK), as well as their nuclear
receptor binding activities. The effect of ceramide pro-
duction was evaluated with the TEST SKINTM LSE-high,
a 3-dimensional cultured human skin model.
Methods
Materials
Glucosylceramide derived from konjac tuber was pur-
chased from Nagara Science (Gifu, Japan). 4-Sphingenineand PCR primers were purchased from Sigma Aldrich
Japan (Tokyo, Japan). Isogen was purchased from Nip-
pon Gene (Tokyo, Japan). Reverse transcriptase,
SYBR-Premix Ex-taq were purchased from TaKaRa
Bio Inc (Shiga, Japan). CCK-8 was purchased from
DOJINDO LABORATORIES (Kumamoto, Japan). NHEK
and the culture medium, Humedia KB2, including the
additive agents, were purchased from Kurabo (Osaka,
Japan). A receptor-cofactor assay system (RCAS) kit
was purchased from Fujikura Kasei (Tokyo, Japan).
TEST SKINTM LSE-high was purchased from Toyobo
(Osaka, Japan).
Preparation of sphingoid bases from glucosylceramide
4,8-Sphingadienine (d18:2) and 4-hydroxy-8-sphingenine
(t18:1) were prepared by acidolysis of konjac glucosylcera-
mide and column chromatography. Glucosylceramide
(1.5 g) was incubated with 400 mL of methanol containing
1 N HCl at 70 °C for 18 h, which was followed by
extraction with 100 mL hexane twice, to eliminate methyl
esters of fatty acids. Sodium hydroxide solution (4 N) was
used to neutralize the water phase. Chloroform and
methanol were added to the mixture to attain a 1:1:1
(v:v:v) ratio of chloroform:methanol:water, which was fol-
lowed by vigorous agitation. The chloroform phase was
collected and concentrated in vacuo. The resulting residue
was dissolved in chloroform and loaded onto a Chroma-
torex NH-DM1020 column (30 mm×170 mm; Fuji Silysia
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Stepwise elution was performed with chloroform/metha-
nol at ratios of 100:0 (150 mL), 90:10 (150 mL), 70:30
(150 mL), and 50:50 (300 mL). The eluents collected were
analyzed by HPLC after solvent evaporation.
HPLC analysis of sphingoid bases
The sphingoids prepared were analyzed by HPLC by
using a Supersphere 100 RP-18(e) column (Merck,
Japan), at 40°C. Isocratic elution was performed using
methanol/distilled water/ammonium acetate in a ratio of
95:5:0.1 (v/v/w) as mobile phase. This was followed by
detection using an evaporative light scattering detector
(ELSD; Alltech, Deerfield, USA).
Cell culture
NHEK was cultured using Humedia-KB2 medium with
growth enhancers, viz., epidermal growth factor, insulin,
hydrocortisone, bovine pituitary extract, and an anti-
microbial agent. NHEK cells (10,000) were seeded in
24-well plates and cultured for 4 d; medium was exchanged
every 2 d. On the fifth day, the medium was replaced with
new medium supplemented with test materials, at the indi-
cated concentrations: 4-sphingenine (5 μg/mL, 16.7 μM);
4,8-sphingadienine (5 μg/mL, 16.8 μM); 4-hydroxy-8-sphin-
genine (5 μg/mL, 15.8 μM); and glucosylceramide
(13 μg/mL, 16.9 μM). After a 24 h cultivation, cells were
used to assess gene expression.
TEST SKINTM LSE-high was cultured in the medium
supplied by the manufacturer, and cultivation was per-
formed according to the instruction manual. The medium
was adjusted at the indicated concentration, 4,8-sphinga-
dienine (2.5 μg/ml, 8.4 μM and 10 μg/ml,33.4 μM),
4-hydroxy-8-sphingenine (2.5 μg/ml, 7.9 μM and
10 μg/ml, 31.7 μM) and glucosylceramide (26 μg/ml,
33.9 μM), and the medium was exchanged 48 h after the
start of cultivation. By 72 h after the start of culturing, the
topmost keratinocytes were removed and analyzed.
RNA extraction and real-time PCR
Total RNA was isolated from NHEK cell lysates 24 h after
adding test samples, using Isogen reagent according to the
manufacturer’s protocol. cDNA was synthesized from total
RNA by using a PrimerScript RT reagent kit with an oligo-
dT primer. Real-time quantitative RT-PCR analysis was
performed using SYBR-Premix Ex-taq and automated
sequence detection systems (StepOne; Applied Biosystems
Japan Ltd, Tokyo, Japan). PCR cycling was performed
using 2 conditions. Condition 1 involved 40 cycles,
each consisting of 15 s at 95°C and 1 min at 60°C,
and was used for serine palmitoyltransferase long chain
(SPTLC) 2, dihydroceramide desaturase (DEGS)-1, cera-
mide synthase (CERS) 2–6, glucosylceramide synthase
(GCS), β-glucocerebrosidase (β-GCS), the elongases ofvery long-chain fatty acids (ELOVL)-1, 4–7, peroxisome
proliferator-activated receptor (PPAR)β/δ, γ amplification.
Condition 2 involved 40 cycles, each consisting of 15 s at
95°C, 15 s at 60°C, followed by 1 min at 72°C, and was
used for sphingomyelin synthase (SMS)-1,2 and sphingo-
myelinase (SMase). The sequences of the primers are
shown in Table 1. The sequences of the primers were
designed by the references [12-21], software and web site.
Nuclear receptor-binding assays
Nuclear receptor-binding assays were performed using
an RCAS kit according to the manufacturer’s protocol.
All the results were normalized to the negative control
(ETOH). GW1929, included in the kit, was used as the
positive control.
Ceramide extraction
The topmost keratinocyte layer was removed from the cul-
tured TEST SKINTM LSE-high and cut into small pieces.
These pieces were soaked in 2 mL of chloroform/methanol
(1:2, v/v) and were left to stand at room temperature for 1 h
to extract the ceramides. The liquid phase was transferred
to a collection tube, and the residual keratinocytes were
extracted in the same manner twice more, using chloro-
form/methanol/distilled water (1:2:0.5, v/v) and chloroform,
and all extracts were pooled. To this was added 600μL of
2.5% KCl and 6 mL of distilled water; the samples were
mixed well, followed by centrifugation at 900× g at room
temperature for 5 min. The lower phase was transferred to
a new tube, and the upper layer was re-extracted with 4 mL
of chloroform by vortexing the tube for 30 s, followed by a
similar centrifugation step. The extract was dried at 50°C
under a stream of nitrogen gas. The residue was dissolved
in 100 μL chloroform/methanol (2:1, v:v) and was stored in
a screw-top bottle at −20°C until use [22].
HPTLC analysis of extracted lipids
The extracted lipids were analyzed by means of high-
performance thin-layer chromatography (HPTLC) on an
HPTLC plate (Merck, Tokyo, Japan); the following mo-
bile phases and distances were used, in this order:
1. Chloroform, for 15 mm
2. Chloroform/acetone/methanol (76:8:16, v:v:v), for
10 mm
3. Chloroform/hexylacetate/acetone/methanol
(86:1:10:4, v:v:v:v), for 70 mm
4. Chloroform/acetone/methanol (76:4:20, v:v:v), for
20 mm
5. Chloroform/diethylether/hexylacetate/ethylacetate/
acetone/methanol (72:4:1:4:16:4, v:v:v:v:v:v), for
75 mm
6. Hexane/diethylether/ethylacetate (80:16:4, v:v:v), for
90 mm
Table 1 Primers for quantitative RT-PCR
Gene Primer sequence (Forward) Primer sequence (Reverse) Reference
SPTLC2 CCAGACTGTCAGGAGCAACCATTA CGTGTCCGAGGCTGACCATA
CerS2 CCGATTACCTGCTGGAGTCAG GGCGAAGACGATGAAGATGTTG [12]
CerS3 ACATTCCACAAGGCAACCATTG CTCTTGATTCCGCCGACTCC [12]
CerS4 CTTCGTGGCGGTCATCCTG TGTAACAGCAGCACCAGAGAG [12]
CerS5 GCCATCGGAATCAGGAC GCCAGCACTGTCGGATGT [12]
CerS6 GGGATCTTAGCCTGGTTCTGG GCCTCCTCCGTGTTCTTCAG [12]
DEGS-1 GCGTTTGGCAGTTGCATTAA CATTGTGGGCAATCTCATGAA designed by Primer Express
SMS-1 GCCAGGACTTGATCAACCTAACC CCATTGGCATGGCCGTTCTTG [13]
SMS-2 CACCCAGTGGCTGTTTCTGA TGCATTCCAGGCACAGGTAGA [13]
aSMase TGGCTCTATGAAGCGATGGC TTGAGAGAGATGAGGCGGAGAC [14]
β-GCS GCTAGGCTCCTGGGATCGAG GTTCAGGGCAAGGTTCCAGTC [15]
GCS GTTCGTCCTCTTCTTGGTGC AGAAGAGAGACACCTGGGAGC [16]
ELOVL-1 ATTCTCCTGACCTACGTGTACTT TTCCGATTAGCCATGATGCGA Primer Bank
ELOVL-4 CATGTGTATCATCACTGTACG AAAGGAATTCAACTGGGCTC [17]
ELOVL-5 TAACAGGAGTATGGGAAGGCA ACCAGAGGACACGGATAATCTT Primer Bank
ELOVL-6 TGCTGCCTTTATATTCGGTGG CCTCAGTTCAAACTTTGCTCGTT Primer Bank
ELOVL-7 TTCCATCATACCATCATGCC CCCAATGCAGAAAGTCCATA [18]
PPARβ/δ ACAGCATGCACTTCCTTCCA TCACATGCATGAACACCGTA [19]
PPARγ ATTCTGGCCCACCAACTTTG TCCATTACGGAGAGATCCACG [20]
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG [21]
Primer sequences used in real-time quantitative RT-PCR in this study. All primers were used with SYBR-Green and their specificities checked using the melting
curve method (60–95°C).
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sprayed with acetate/H2PO4/H3PO4/0.5% CuSO4 solution
(5:1:1:95, v:v:v:v) and heated to 160 °C to visualize the
separated lipids. The colored plate was immediately
scanned using a densitometer.Statistical analysis
All the data are presented as mean ± SD values. Statis-
tical significance was determined using Student’s t-test;
p < 0.05 was considered to be statistically significant.Table 2 Sphingoid composition of konjac
glucosylceramide






Sphingoid bases are presented in abbreviated style. d18:0 has 2 hydroxyl
groups and 18 carbons, without any double bonds, whereas t18:1 has 3
hydroxyl groups, and 18 carbons, with 1 double bond.Results
Ceramide de novo synthesis-related gene expression
Purified glucosylceramide (≥99%) from konjac tuber was
digested to sphingoids in the presence of hydrochloric
acid. Table 2 shows the composition of sphingoids
analyzed by GC-MS. The major sphingoid moieties
of konjac glucosylceramide are 4,8-sphingadienine and
4-hydroxy-8-sphingenine. We examined the effects of
the major sphingoids derived from konjac glucosylcera-
mide on the expression of genes related to de novo syn-
thesis of ceramide by using real-time quantitative PCR.
First, we checked the toxicity of the sphingoids to the
NHEK cells. CCK-8 was used to measure the cell viabil-
ity after 24 h exposure of sphingoids. There were nodifferences between cells after sphingoids and vehicle
treatment.
Then we used the assessed the expression of these
genes in d18:2 and t18:1-treated NHEK cells. As shown
in Fig. 2A, the expression of SPTLC2, CerS3, DEGS-1,
SMS-1, aSMase, and GCS increased by 1.1-fold, 2.4-fold,
1.4-fold, 1.2-fold, 2.2-fold, and 2.6-fold, respectively,
following exposure of the cells to 5 μg/mL d18:2.
The expression of CerS3, aSMase, and GCS increased by
2.5-fold, 4.7-fold, and 1.3-fold, respectively, in the pres-
ence of 5 μg/mL t18:1.
Second, we tested the expression of ELOVL-1, ELOVL-4,
ELOVL-5, ELOVL-6, and ELOVL-7. As shown in Fig. 2B,
the expression of ELOVL-1, ELOVL-4, and ELOVL-7
AB
Figure 2 Expression of genes involved in de novo synthesis of ceramides in sphingoid-treated NHEK cells. (A) Expression of genes
involved in de novo synthesis of ceramides. (B) Expression of ELOVL genes and PPAR genes. Real-time PCR was performed at 24 h after treatment
of NHEK cells with sphingoids or glucosylceramide. Vehicle-treated (EtOH at a final concentration of 0.1%, which did not affect cell viability) NHEK
cells were used as the control; gene expression was evaluated relative to these control cells. As test treatments, 5 μg/mL of 4-sphingenine (Sph),
d18:2, or t18:1, or 13 μg/mL of glucosylceramide (GlcCer) was used. All the results are shown as mean± SD (n = 4). *p< 0.05, **p< 0.01,
significantly different from the level in the vehicle-treated control cells (Student’s t-test).
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the presence of 5 μg/mL d18:2. Moreover, in the presence
of 5 μg/mL t18:1, the expression of these 3 genes increased
by 1.5-fold, 3.4-fold, and 3.3-fold, respectively.
We also tested the expression of PPARβ/δ, and PPARγ,
which are known to promote the differentiation of kerati-
nocytes. As shown in Fig. 2B, expression of PPARβ/δ in
the presence of 5 μg/mL d18:2 or t18:1 increased by
2.0-fold and 3.0-fold, respectively. PPARγ expression
increased by 1.4-fold in the presence of 5 μg/mL t18:1. In
contrast, neither glucosylceramide nor 4-sphingenine had
any marked effects on the expression of these genes.PPARγ ligand
The ability of d18:2 and t18:1 to act as ligands of PPARγ
was assessed using nuclear receptor assays. As shown in
Fig. 3, no binding of glucosylceramide to PPARγ was
observed. In contrast, d18:2 and t18:1 showed efficient
binding to PPARγ. These results suggested that d18:2
and t18:1 are ligands of PPARγ and thus participate in
positive feedback regulation of PPARγ activity, including
induction of differentiation in keratinocytes.Ceramide sysnthesis in 3-dimensional human skin model
To assess the upregulation of ceramide production by
d18:2 and t18:1, we used a reconstituted human skin
model, TEST SKINTM LSE-high. As shown in Fig. 4, we
identified 7 ceramide spots [23]; d18:2 treatments of the
skin model increased the intensities of ceramide III (NP)
spots, while t18:1 treatments increased the intensities of
ceramide I (EOS), II (NS), and III (NP), compared to
vehicle (ethanol) and glucosylceramide treatments. These
results are summarized in Table 3, in which the digitizedd18:2
Figure 3 Activation of PPARγ by sphingoids. The ability of 2.5 and 10 μ
activate PPARγ was measured using a receptor cofactor assay system. As po
activity was normalized to the absorption at 450 nm. All the results are sho
different from the levels in vehicle-treated control cells.intensities of the spots are recorded. These results indi-
cate that d18:2 and t18:1 induce ceramide production in
a human skin model.Discussion
Although previous reports have demonstrated that
dietary glucosylceramide can decrease TEWL from
human skin [24], the mechanism was unclear. Ueda
et al. reported that orally administrated ceramide was
distributed to the dermis after intestinal absorption,
followed by transfer from the dermis to the epidermis
[25]. Ishikawa et al. also showed that dietary glucosyl-
ceramide was degraded into sphingoids, which were
absorbed through the intestinal epithelial cells of
rats and were subsequently also found in the lymph
fluid in these rats [11]. Another study showed that
4-hydroxysphinganine could activate the PPARs [26]
that are the key regulators of keratinocyte differenti-
ation [27].
Keratinocyte differentiation is closely related to internal
ceramide synthesis [28]. It is unlikely that orally ingested glu-
cosylceramide would specifically localize to the skin because
the amount of ingested glucosylceramide is simply too little
to enhance ceramide levels in the skin. We hypothesized
that sphingoids are the most likely effectors of ceramide pro-
duction in the skin. In the present study, we used d18:2 and
t18:1 as candidates because they were the major constituents
of konjac glucosylceramide, as shown in Table 2. Daily oral
intake of 1.8 mg konjac glucosylceramide for 28 days had
improved transepidermal water loss (TEWL) of the skin|
in a human trial [10]. Previous report [26] showed that phy-
toceramide activated PPARs at the concentration of above
10 μM. According this report, it was 10 μM that we(µg/ml)
t18:1
g/mL of sphingoids or 26 μg/mL glucosylceramide to bind and
sitive control, 8 mM of GW1929 was used. Horseradish peroxidase








Ctl  GlcCer  2.5      5 2.5       5 ( µg/ml)
d18:2 t18:1
Figure 4 HPTLC of ceramides extracted from a 3-dimensional
human skin model treated with sphingoids. Two wells containing
3-dimensional human skin model samples were pooled per sample.
The weight of the keratinocyte layer was measured soon after the
removal of this layer from the model; the values for all samples were
subsequently adjusted to this weight. The same amount of lipids
extracted from the keratinocyte layer of all samples was loaded onto
the HPTLC plate. To visualize the ceramides, the HPTLC plate was
treated with acetate/H2PO4/H3PO4/0.5% CuSO4 solution and heated.
Abbreviations of Cer I to VII represent Ceramide I to VII, these are
classical names base on rate of flow in TLC. Recent names based on
the structure, the combination of fatty acid and sphingoids, were
shown in the parenthesis. A = α-hydroxy fatty acid, EO= Esterified ω-
hydroxy fatty acid, N =Non-hydroxy fatty acid, P = Phytosphingosine,
S = Sphingosine, H = 6-Hydroxy sphingosine.
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of ceramide de novo synthesis. In this study (in vitro),
the concentration was adopted from 8.4 (2.5 μg/ml)
to 33.4.μM (10 μg/ml) for sphingoids and glucosyl-
ceramide. As a result, the upregulation of ceramide
de novo synthesis, the activation of PPARγ and the
induction of ceramides in 3-dimensional human skin
model have been cofirmed.Table 3 Levels of ceramide in a 3-dimensional human skin mo
Ctl GlcCer d18:2 2.5 μg/mL
Cer I (EOS) 1.00 0.82 0.87
Cer II (NS) 1.00 0.78 0.92
Cer III (NP) 1.00 1.24 1.19
A 3-dimensional human skin model, TEST SKINTM, was cultured in medium containin
from the topmost keratinocyte layer and analyzed by HPTLC. The levels of ceramide
densities in vehicle-treated control samples.Real-time quantitative RT-PCR was performed using
NHEK cells that had been treated with sphingoids and
glucosylceramide. We tested the effects of d18:2 and
t18:1 on the expression of genes related to de novo cera-
mide synthesis, including SPTLC2, DEGS-1, and CerS2-b
[29,30], the ELOVL family, and PPARs. Glucosylceramide
and 4-sphingenine had no noticeable effects on the
expression of these genes; in contrast, d18:2 and t18:1
could activate the expression of these genes. Among the
products of the genes activated, CerS3 catalyzes the pro-
duction of epidermal ceramides [7], and CerS2 regulates
ELOVL-1–mediated synthesis of C22-CoA from C18 via
C20, which is an essential step in the production of C24
ceramide [31]. Our data therefore indicated the possibil-
ity of induction of keratinocyte differentiation and
ceramide production as a result of treatment with d18:2
and t18:1.
We next attempted to assess the activatory effects of
d18:2 and t18:1 on PPARγ by using in vitro binding assays.
We found that d18:2 and t18:1 could activate PPARγ,
whilst glucosylceramide could not. The results of our gene
expression studies and binding assays indicated that d18:2
and t18:1 promote the differentiation of keratinocytes and
stimulate endogenous ceramide production.
When we investigated the effects of these compounds
on TEST SKINTM LSE-high, we observed that ceramides
I, II, and III were induced by d18:2 and t18:1 treatment.
This indicated that d18:2 and t18:1 promoted not only
the induction of gene expression but also the production
of ceramides in human skin.
As mentioned earlier, various reactions were induced
by d18:2 and t18:1 but not by 4-sphingenine. The major
structural difference between the active sphingoids and
4-sphingenine is a C8–C9 double bond. A previous re-
port demonstrated that 4-hydroxysphinganine (t18:0)
could act as a ligand for PPARs [26,32]. This is the first
report that t18:1 and d18:2 are the agonists for PPARγ. As
4-sphingenine (d18:1) did not act as PPARγ agonist, some
functional molecular structure, for example 4-hydroxy
(t18:0 and t18:1) or C8 double bond (t18:1 and d18:2),
might be needed to activate PPARs.
Nine species of sphingoids are commonly found in
plants [33], and many sources of glucosylceramide other
than konjac tuber exist, e.g., rice bran, corn, apple, anddel treated with sphingoids




g sphingoids or glucosylceramide for 72 h. Ceramides were then extracted
s were assessed by densitometry; results were evaluated relative to the
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d18:2 and t18:1, but these sphingoids are not as abun-
dant as in konjac, suggesting that konjac is the most
effective source of material for improving skin ceramide
production.
Water retention of the skin decreases because of aging,
UV exposure, and diseases such as atopic dermatitis [7].
These factors cause the depletion of skin ceramides and
a reduction in hyaluronic acid, and lead to inflammation
and wrinkling of the skin. In contrast, dietary glucosyl-
ceramides can improve the condition of the skin [34,35].
Because the amount of glucosylceramide ingestion is so
limited, it is believed that improvement of the skin is not
due to the direct localization of glucosylceramide to the
skin. In this study, we have shown that at least part of
the mechanism involves a triggering of the ceramide syn-
thesis pathway by d18:2 and t18:1. Further studies may
help elucidate the complete mechanism underlying effi-
cient improvement of skin conditions through dietary
glucosylceramides, thereby contributing to human health
and wellbeing.
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